In 2023, West Virginia had the highest share of adults (**** percent) who had ever been told by a doctor that they had diabetes. This statistic represents the percentage of adults in the United States who had ever been diagnosed diabetes as of 2023, by state.

It was estimated that as of 2023, around **** million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the seventh leading cause of death in the United States, accounting for ******percent of all deaths. What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around ** million men and ** million women in the United States had prediabetes. However, according to the CDC, around ** percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are California, Hawaii, and New Mexico. The prevalence of diabetes in the United States As of 2023, around *** percent of adults in the United States had been diagnosed with diabetes, an increase from ****percent in the year 2000. Diabetes is much more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to just ****percent of those aged 20 to 39 years. The states with the highest prevalence of diabetes among adults are West Virginia, Mississippi, and Louisiana, while Utah and Colorado report the lowest rates. In West Virginia, around ** percent of adults have been diagnosed with diabetes.

In 2023, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to *** percent. This was an increase from *** percent in the year 2000. How many people in the United States have diabetes? It was estimated that in 2023, almost **** million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only **** million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults, with around ** percent of those aged 60 years and older diagnosed with diabetes, compared to ** percent of those aged 40 to 59 years. Leading diabetic states In 2023, the U.S. states with the highest prevalence of diagnosed diabetes were West Virginia, Mississippi, and Louisiana. Just over ** percent of adults in West Virginia had diabetes that year. In Utah, just under ***** percent of adults have been diagnosed with diabetes, the lowest share in the United States.

China is the country with the highest number of diabetics worldwide, with around *** million people suffering from the disease. By the year 2050, it is predicted that China will have around *** million people with diabetes. Death from diabetes Diabetes is one of the leading causes of death worldwide, accounting for **** million deaths in 2021. Diabetes at least doubles one’s chance of dying prematurely, and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where around *** million people died from the disease in 2024. Obesity One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around ** percent of the adult population was obese in 2023, compared to ** percent of the population in 2011.

It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

By 2050, the Western Pacific region is forecast to have the highest number of diabetic people worldwide, with some 254 million people aged between 20 and 79 years. Diabetes in the future Between 2024 and 2050, the number of diabetics is set to increase in all regions worldwide. Diabetes rates are expected to increase the most in Africa, by roughly 142 percent. Throughout this period, Europe is projected to show the smallest increase, with about 10 percent. In 2050, the countries with the highest number of diabetics are expected to be China with some 168 million and India with about 157 million. At that time, about 43 million people are projected to have diabetes in the United States. Children with type 1 diabetes In 2024, the country with the highest estimated number of children and adolescents (between the ages of 0 and 19) with type 1 diabetes was India, which had some 301 thousand diabetic children and adolescents. The United States came second with around 197 thousand. Considering the U.S. population is significantly smaller than that of India, there is a higher percentage of children with type 1 diabetes in the United States.

The United States Diabetes Care Drugs and Devices Market is Segmented by Product Type (Devices [Monitoring Devices, and More] and Drugs [Insulin Drugs, and More]), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Age Group (Adult, Geriatric, and More), and Distribution Channel (Offline and Online). The Market and Forecasts are Provided in Terms of Value (USD).

Analysis of ‘Selected Trend Table from Health, United States, 2011. Diabetes prevalence and glycemic control among adults 20 years of age and over, by sex, age, and race and Hispanic origin: United States, selected years 1988 - 1994 through 2003 - 2006’ provided by Analyst-2 (analyst-2.ai), based on source dataset retrieved from https://catalog.data.gov/dataset/2c42e2e5-46cb-400c-8333-d387c5ea2614 on 27 January 2022.

--- Dataset description provided by original source is as follows ---

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

--- Original source retains full ownership of the source dataset ---

In 2024, Pakistan had the highest prevalence of diabetes worldwide, with around ** percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections. Costs As of 2024, there were almost *** million people worldwide who had diabetes. With such a huge number of people suffering from this disease, it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around ***** billion U.S. dollars on diabetes health expenditure in 2024. The countries with the highest spending per patient with diabetes include Switzerland, the United States, and Norway. Death Diabetes is among the leading ten causes of death worldwide, accounting for around **** million deaths in 2021. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. The risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes, followed by North America and the Caribbean.

The Diabetes Prevention Program (DPP) is a clinical trial that investigated whether modest weight loss through dietary changes and increased physical activity or treatment with the oral diabetes drug metformin (Glucophage) could prevent or delay the onset of type 2 diabetes in high risk individuals with prediabetes.

The study enrolled overweight persons with elevated fasting and post-load plasma glucose concentrations. Participants were randomized to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes of physical activity per week. The primary outcome measure was development of diabetes, diagnosed on the basis of an annual oral glucose-tolerance test or a semiannual fasting plasma glucose test, according to the 1997 criteria of the American Diabetes Association: a value for plasma glucose of 126 mg per deciliter (7.0 mmol per liter) or higher in the fasting state, or 200 mg per deciliter (11.1 mmol per liter) or higher two hours after a 75-g oral glucose load. Participation in DPP continued after a diagnosis of diabetes was made, although study medication was discontinued and participants were sent to their local primary care provider for treatment of diabetes once fasting glucose was > 140 mg/dl.

Results showed that both lifestyle changes and treatment with metformin reduced the incidence of diabetes in persons at high risk compared with placebo. Furthermore, the lifestyle intervention was more effective than metformin in preventing the onset of diabetes.

Supplemental measurements were collected using biospecimens that were obtained during the original DPP clinical trial. These measurements included antibodies, biomarkers, hormones, and vitamin D levels to assess the relationships between sex hormones, diabetes risk factors, and the progression to diabetes. The supplemental data showed that sex hormones were associated with diabetes risk in men, but these associations were not found in women. Furthermore, obesity and glycemia were more important predictors of diabetes risk than sex hormones.

The size of the North America Diabetes Pharmaceutical market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.58% during the forecast period.Diabetic drugs refer to a class of medicine that regulates and treats chronic situations of having a high level of blood sugar, diabetic complications. The mechanism of action varies from the effects on insulin production which enhances the patient's insulin sensitivity or directly lowers the levels of blood glucose. Common categories include insulins, oral antidiabetic drugs, and the newer classes classified as GLP-1 receptor agonists and SGLT-2 inhibitors.The North American diabetes pharma market is one of the biggest and most developed in the world. A high prevalence of diabetes in the region, along with significant investment in healthcare research and development, has led to a broad spectrum of innovative diabetes medications that are available. Among these, the United States has a significant role as a hub for conducting research and developments in the pharmaceutical sector. A large number of companies are involved in developing novel therapies for diabetes.Some of the major growth factors of the diabetes pharmaceutical market in North America are an aging population, increasing incidence of obesity and sedentary lifestyle, and better drug delivery systems. In fact, the North American market has the prospects of being a major player in the global diabetes pharmaceutical industry since the demand for effective and safe diabetes treatments keeps growing up. Recent developments include: May 2022: The US FDA approved Eli Lilly and Company's Mounjaro (tirzepatide) injection as an adjunct to diet and exercise. It is to enhance glycemic control in adult patients with type 2 diabetes. A single molecule, Mounjaro is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist., March 2022: Oramed announced that ORMD-0801 is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule with the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed is also developing an oral GLP-1 analog capsule (ORMD-0901).. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The Oral anti-diabetic drugs segment is expected to register the highest CAGR in the North America Diabetes Drugs Market.

The US diabetes devices market, a significant segment of the global market, is experiencing robust growth, driven by the rising prevalence of diabetes and an aging population. The market, valued at approximately $25.16 billion in 2025, is projected to expand at a Compound Annual Growth Rate (CAGR) of 6.27% from 2025 to 2033. This growth is fueled by several key factors: increasing adoption of continuous glucose monitoring (CGM) systems offering improved diabetes management, technological advancements leading to smaller, more user-friendly devices, and growing awareness of the benefits of proactive diabetes care. The market is segmented into monitoring and management devices. Within monitoring, self-monitoring blood glucose (SMBG) devices, including glucometers, test strips, and lancets, remain a substantial portion, although CGM is experiencing faster growth due to its real-time data capabilities and improved patient outcomes. The management device segment is dominated by insulin delivery systems like insulin pumps, syringes, pens, and jet injectors, with insulin pumps showing particularly strong growth prospects due to their convenience and efficacy in managing insulin delivery. Competitive intensity is high, with major players like Abbott, Medtronic, Dexcom, and Novo Nordisk vying for market share through continuous innovation and strategic partnerships. The North American region, particularly the US, holds a significant market share owing to high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support for innovative medical technologies. The market's growth trajectory is expected to remain positive through 2033, although certain restraints could influence the pace. These include high costs associated with some devices, particularly CGMs and insulin pumps, creating access barriers for some patients. However, increasing insurance coverage and the development of more affordable alternatives are mitigating these challenges. Furthermore, technological advancements, such as the integration of artificial intelligence and machine learning in diabetes management, are expected to further enhance the market's potential. Companies are focusing on developing integrated systems that combine CGM with insulin delivery, providing a more holistic approach to diabetes management. This trend will likely drive further growth and consolidation within the market. Future success will depend on companies' ability to innovate, offer competitive pricing strategies, and address the evolving needs of patients. Recent developments include: August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin., March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.. Key drivers for this market are: Increasing Number of Preterm and Low-weight Births, Advanced Technology in Fetal and Prenatal Monitoring. Potential restraints include: Stringent Regulatory Procedures. Notable trends are: Growing Diabetes and Obesity Population in the United States.

The United States self-monitoring blood glucose (SMBG) market, valued at $7.62 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of diabetes and the rising adoption of advanced SMBG devices. The market's Compound Annual Growth Rate (CAGR) of 6.40% from 2019 to 2024 indicates a steady expansion, which is expected to continue through 2033. Key growth drivers include the increasing diabetic population, particularly among older adults, the rising awareness about diabetes management, and technological advancements leading to more accurate, user-friendly, and convenient glucose monitoring devices. The market is segmented into glucometer devices, test strips, and lancets, with glucometer devices likely representing the largest segment due to the technological innovations leading to smaller, more sophisticated devices and integration with mobile apps for data tracking and management. Furthermore, the growing demand for continuous glucose monitoring (CGM) systems, though not explicitly stated in the provided data, is a significant emerging trend that is likely contributing to market expansion. While challenges exist, such as the high cost of treatment and the potential for inaccuracies with some devices, the market's overall trajectory remains positive due to the sustained need for effective diabetes management. The competitive landscape is characterized by established players like Abbott Diabetes Care, Roche Holding AG, and LifeScan, who hold significant market share. These companies are engaged in continuous innovation to maintain their market dominance by developing technologically advanced devices and expanding their global reach. Smaller companies contribute significantly to innovation and competition, particularly in the development of less expensive and more accessible devices. However, the market's success is closely tied to the broader healthcare landscape, including government regulations, insurance coverage policies, and public health initiatives aimed at diabetes prevention and management. Further research is required to fully quantify the impact of these factors on specific market segments and individual companies within the US SMBG market. Recent developments include: January, 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes-one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., January 20, 2022: Roche announced the launch of the COBAS pulse system in selected countries accepting the CE mark. The COBAS pulse system marks Roche Diagnostics' newest generation of connected point-of-care solutions for professional blood glucose management. The COBAS pulse system combines the form factor of a high-performance blood glucose meter with simple usability and expanded digital capabilities like those of a smartphone. Following first commercial availability under the CE mark in select markets, Roche plans to seek CE IVDR and FDA clearance for the Cobas Pulse System in other global markets.. Notable trends are: Rising Diabetes Prevalence in the United States.

This dataset contains number and percentage of diabetes patients in the US during 2013 grouped by ZIP code. The prevalence and incidence of diabetes have increased in the United States in recent decades, no studies have systematically examined long-term, national trends in the prevalence and incidence of diagnosed diabetes. The prevalence of diabetes increased substantially between 2000 and 2007, mainly because there are more patients with a new diagnosis each year than those who die. The increase observed by 2007 almost reached the World Health Organization prediction for 2030.

Human Insulin Regular Market Outlook

The global human insulin regular market size was valued at approximately $6.2 billion in 2023 and is projected to reach around $10.1 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.7%. The growth of this market is primarily driven by the increasing prevalence of diabetes worldwide, advancements in insulin delivery systems, and rising awareness about diabetes management. The market size is poised for substantial growth due to the increasing number of diabetic patients, improved healthcare infrastructure, and technological advancements in insulin administration.

The surge in diabetes cases, particularly Type 2 diabetes, is one of the major growth factors for the human insulin regular market. Sedentary lifestyles, unhealthy eating habits, and rising obesity rates contribute significantly to the increasing diabetes prevalence. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a number expected to rise considerably by 2030. This surge underscores the growing need for effective diabetes management solutions, thus driving the demand for human insulin regular.

Technological advancements and innovations in insulin delivery systems also play a crucial role in market growth. The development of insulin pens, smart insulin pumps, and continuous glucose monitoring systems has revolutionized diabetes management by offering more accurate and user-friendly options for insulin administration. These advancements not only improve patient compliance but also enhance the quality of life for diabetic patients. The integration of digital health solutions and artificial intelligence in diabetes care further propels the market growth, providing a more holistic and personalized approach to diabetes management.

Government initiatives and favorable reimbursement policies are another significant factor contributing to market growth. Many countries have implemented national diabetes programs aimed at early diagnosis, effective management, and prevention of diabetes-related complications. These initiatives often come with financial support for both patients and healthcare providers, making insulin more accessible and affordable. For instance, programs in the United States, Canada, and several European countries provide subsidies and insurance coverage for insulin, thereby encouraging more patients to adhere to their prescribed insulin regimens.

Regionally, North America holds a substantial share of the human insulin regular market due to the high prevalence of diabetes and well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period. Factors such as increasing urbanization, rising healthcare expenditure, and growing awareness about diabetes management contribute to this growth. The presence of a large diabetic population in countries like China and India also fuels the demand for human insulin regular in the Asia Pacific region.

Product Type Analysis

The human insulin regular market is segmented by product type into vials, cartridges, and prefilled pens. Vials have traditionally been the most commonly used form of insulin due to their cost-effectiveness and widespread availability. They have been the cornerstone of insulin therapy for decades, particularly in hospital settings where large quantities of insulin are required. Despite the advent of more advanced delivery systems, vials remain a popular choice, especially in lower-income regions where affordability is a significant concern.

Cartridges, on the other hand, offer a more convenient and portable option for insulin administration. They are typically used with insulin pens, which provide more precise dosing and ease of use compared to vials and syringes. This segment has seen significant growth due to the increasing preference for insulin pens among both patients and healthcare providers. The demand for cartridges is also driven by the growing trend towards home-based diabetes management, as they are more user-friendly and reduce the risk of dosage errors.

Prefilled pens represent the most advanced and convenient form of insulin delivery currently available. These devices come preloaded with insulin and are designed to be disposable after use, eliminating the need for vial and syringe handling. Prefilled pens are particularly beneficial for elderly patients or those with dexterity issues, as they simplify the injection process and improve adherence to insulin therapy. This segment is expe

Background: Type 2 diabetes rates in the general population have risen with the growing obesity epidemic. Knowledge of temporal patterns and factors associated with comorbid diabetes among stroke patients may enable health practitioners and policy makers to develop interventions aimed at reducing diabetes rates, which may consequently lead to declines in stroke incidence and improvements in stroke outcomes. Methods: Using the Nationwide Inpatient Sample (NIS), a nationally representative data set of US hospital admissions, we assessed trends in the proportion of acute ischemic stroke (AIS) patients with comorbid diabetes from 1997 to 2006. Independent factors associated with comorbid diabetes were evaluated using multivariable logistic regression. Results: Over the study period, the absolute number of AIS hospitalizations declined by 17% (from 489,766 in 1997 to 408,378 in 2006); however, the absolute number of AIS hospitalizations with comorbid type 2 diabetes rose by 27% [from 97,577 (20%) in 1997 to 124,244 (30%) in 2006, p < 0.001]. The rise in comorbid diabetes over time was more pronounced in patients who were relatively younger, Black or ‘other’ race, on Medicaid, or admitted to hospitals located in the South. Factors independently associated with higher odds of diabetes in AIS patients were Black or ‘other’ versus White race, congestive heart failure, peripheral vascular disease, history of myocardial infarction, renal disease and hypertension. Conclusions: Although hospitalizations for AIS in the US decreased from 1997 to 2006, there was a steep rise in the proportion with comorbid diabetes (from 1 in 5 to almost 1 in 3). Specific patient populations may be potential targets for mitigating this trend.

In 2024, around 16 percent of adults between the ages of 20 and 79 had diabetes in Turkey. Other selected countries with a high prevalence of diabetes that year included Mexico, the United States, and Portugal. Diabetes is a metabolic disease that causes high blood sugar levels. Diabetes worldwide In 2024, an estimated 11 percent of the global adult population had diabetes. In concrete numbers, there were about 589 million diabetic adults (20-79 years) worldwide in 2024, and this total is predicted to grow to approximately 852.5 million by the year 2050. Spending per patient The country that spent the most on patients with diabetes in 2024 was Switzerland. At that time, providing for a diabetic patient in Switzerland cost an average of over 12 thousand U.S. dollars. The United States stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. Bangladesh had the lowest annual diabetes-related health expenditures per person, with just 74 U.S. dollars.

The North American insulin delivery pens market, valued at $11.99 billion in 2025, is projected to experience robust growth, driven by the rising prevalence of diabetes, an aging population, and increasing adoption of advanced insulin delivery systems. The market's Compound Annual Growth Rate (CAGR) of 4.87% from 2025 to 2033 indicates a steady expansion, with significant contributions from both disposable insulin pens and cartridges used in reusable pens. The United States constitutes the largest segment, reflecting its higher diabetic population and advanced healthcare infrastructure. Canada holds a significant share, while the "Rest of North America" segment demonstrates a promising growth trajectory, fueled by increasing diabetes awareness and improved healthcare access. Competitive dynamics are shaped by major players such as Novo Nordisk, Sanofi, and Eli Lilly, who continually innovate to improve product efficacy, convenience, and patient adherence. These companies leverage their established distribution networks and brand recognition to maintain market leadership. However, emerging players and technological advancements, such as the development of smart insulin pens with integrated monitoring and data management capabilities, present both opportunities and challenges for the established market leaders. The market faces restraints such as high treatment costs, potential for insulin allergy, and the need for patient education and training on proper usage. Nevertheless, the long-term growth outlook remains positive, driven by the ongoing need for effective diabetes management solutions. The market segmentation highlights the significance of disposable insulin pens and cartridges in reusable pens, offering varying levels of convenience and cost-effectiveness to patients. Geographical segmentation reveals the substantial market presence of the United States and Canada, reflecting a high incidence of diabetes and well-established healthcare systems. The forecast period (2025-2033) suggests continued expansion, fueled by technological advancements and increased patient awareness. Strategic partnerships between pharmaceutical companies and medical device manufacturers are likely to further enhance market penetration and improve access to advanced insulin delivery systems. Moreover, government initiatives promoting diabetes prevention and management will significantly contribute to market growth throughout the forecast period. Future market trends likely include the increased integration of digital health technologies, personalized medicine approaches to insulin therapy, and the development of novel insulin analogs with enhanced efficacy and safety profiles. Recent developments include: March 2023: Novo Nordisk announced that the company would drop prices for vials and pens of NovoLog and other insulin brands by 75 percent beginning January 1, 2024, in the United States. There is expected to be a 65 percent price reduction for some of the other Novo Nordisk insulin brands., June 2022: Cequr, the leader in wearable diabetes technology, released its newest and most innovative insulin delivery device yet, the Insulin Pen 2.0TM. The pen was small enough to always be worn on the user's body, and it also featured a built-in blood glucose meter so that users could track their blood sugar throughout the day. The insulin pen also had an integrated injection system that did not require any manual pumping or priming to inject insulin into the body, making it much easier and faster to administer than other types of insulin pumps currently on the market.. Notable trends are: Insulin cartridges in reusable pens are expected to witness significant growth over the forecast period.

According to the Juvenile Diabetes Research Foundation (JDRF), almost 1.25 million people in the United States (US) have type 1 diabetes, which makes them dependent on insulin injections. Nationwide, type 2 diabetes rates have nearly doubled in the past 20 years resulting in more than 29 million American adults with diabetes and another 86 million in a pre-diabetic state. The International Diabetes Federation (IDF)has estimated that there will be almost 650 million adult diabetic patients worldwide at the end of the next 20 years (excluding patients over the age of 80). At this time, pancreas transplantation is the only available cure for selected patients, but it is offered only to a small percentage of them due to organ shortage and the risks linked to immunosuppressive regimes. Currently, exogenous insulin therapy is still considered to be the gold standard when managing diabetes, though stem cell biology is recognized as one of the most promising strategies for restoring endocrine pancreatic function. However, many issues remain to be solved, and there are currently no recognized treatments for diabetes based on stem cells. In addition to stem cell research, severalβ-cell substitutive therapies have been explored in the recent era, including the use of acellular extracellular matrix scaffolding as a template for cellular seeding, thus providing an empty template to be repopulated with β-cells. Although this bioengineering approach still has to overcome important hurdles in regard to clinical application (including the origin of insulin producing cells as well as immune-related limitations), it could theoretically provide an inexhaustible source of bio-engineered pancreases Date Submitted: 2021-01-13